Drug name - Gocovri

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889740 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895616 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8796337 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895617 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895618 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895614 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895615 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8389578 ADAMAS PHARMA Composition and method for treating neurological disease Jan, 2028

(5 years from now)

US9877933 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US9867791 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US9867792 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US11197835 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US8741343 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US9867793 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US10646456 ADAMAS PHARMA Methods of administering amantadine Jun, 2034

(11 years from now)

US10154971 ADAMAS PHARMA Methods of administering amantadine Dec, 2034

(12 years from now)

US11065213 ADAMAS PHARMA Amantadine compositions and preparations thereof Aug, 2038

(15 years from now)

US11077073 ADAMAS PHARMA Methods of using amantadine compositions Aug, 2038

(15 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia in patients with parkinson's disease receiving immediate release levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia, decreasing off time, and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 68.5MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 137MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.